WILMINGTON, Mass., May 11, 2015 /PRNewswire/ -- Implant
Sciences Corporation (OTCQB:IMSC), a leading manufacturer of
explosives trace detection (ETD) and drugs trace detection
solutions for homeland security applications, today announced that
the company has been granted three new patents by the U.S. Patent
and Trademark Office.
The patents, captioned "Non-Radioactive Ion Source Using High
Energy Electrons", "Chemical Analysis Using Hyphenated Low and High
Field Ion Mobility", and "Selective Ionization Using High-Frequency
Filtering of Reactive Ions," expand Implant Sciences' intellectual
property protection and are expected to lead to even more effective
company products.
"Implant Sciences is committed to providing the best and most
innovative technology for our customers. We believe that the first
of these three new patents, our newest non-rad ionization method,
gives Implant Sciences a true competitive advantage in the field.
This new design is durable, low-cost, and is compatible with
high-volume manufacturing. We believe that the design, which also
makes the unit easier to service in the field, will further
simplify trace detection ownership and increase customer
satisfaction," noted Todd Silvestri,
Implant Sciences' Vice President of Technology.
"Implant Sciences' other two new patents seek to dramatically
improve some of the inherent limitations associated with the
conventional ionization physics and chemistry currently deployed in
ion mobility systems, primarily False Alarm Rates (FAR) and
selectivity. The innovation in these two patents, namely
hyphenating of Ion Mobility Spectrometry (IMS) and Differential
Mobility Spectrometry (DMS), leads to an even higher system
resolution, which increases the range of detectable threats for the
system," stated Dr. Bill McGann, CEO
of Implant Sciences.
"Being able to select the type of reactive ions we want to
generate, via the high-frequency filtering patent, adds another
dimension of separation, leading to improved selectivity.
Both of these patents should allow us to detect and identify
a broader range of threats, including homemade explosives (HMEs),
masking agents, and other new threats. We expect this will
lead to important, real-life implications for our customers, where
lives depend on technology such as ours to detect emerging
terrorist threats," Dr. McGann added.
About Implant Sciences
Implant Sciences is a leader in developing and manufacturing
advanced detection capabilities to counter and eliminate the
ever-evolving threats from explosives and drugs. The company's team
of dedicated trace detection experts has developed proprietary
technologies used in its commercial products, thousands of which
have been sold across more than 60 countries worldwide. The
company's ETDs have received approvals and certifications from
several international regulatory agencies including the TSA in the
U.S., ECAC in Europe, CAAC and the
Ministry of Public Safety in China, Russia FSB, STAC in France, and the German Ministry of the
Interior. It has also received the GSN Homeland Security Award for
"Best Explosives Detection Solution" two years in a row (2013 and
2014). All Implant Sciences products are recognized as
Qualified Anti-Terrorism Technologies by the Department of Homeland
Security. For further details on the Company and its products,
please visit the Company's website at www.implantsciences.com.
Cautionary Note Regarding Forward-Looking Statements
This press release and any statements of employees,
representatives and partners of Implant Sciences Corporation (the
"Company") related thereto contain or may contain certain
"forward-looking statements," as that term is defined in the
Private Securities Litigation Reform Act of 1995. Such
statements may include, without limitation, statements with respect
to the Company's plans, objectives, projections, expectations and
intentions and other statements identified by words such as
"projects," "may," "will," "could," "would," "should," "believes,"
"expects," "anticipates," "estimates," "intends," "plans,"
"potential" or similar expressions. Such statements are based
on management's current expectations and are subject to significant
risks and uncertainties (many of which are beyond the Company's
control) that could cause the Company's actual results to differ
materially from the forward-looking statements. Such risks and
uncertainties include, but are not limited to, the risks that our
markets are subject to technological change and our ability to
generate revenue and profit will depend on our ability to develop
and introduce new products; our ability to compete will depend on
our ability to develop, acquire or license new patents and other
intellectual property and operate without infringing on the
proprietary rights of others; we may not obtain the patents we have
applied for; the validity and breadth of claims in technology
patents involve complex legal and factual questions and, therefore,
may be highly uncertain; any patents we may obtain may be may be
challenged and subsequently invalidated; we may incur substantial
costs in asserting our patent rights; and other risks and
uncertainties described in our filings with the Securities and
Exchange Commission, including our most recent Forms 10-K, 10-Q and
8-K. In light of these risks and uncertainties, readers are
cautioned that actual results may differ significantly from those
described or anticipated in the forward-looking statements.
The Company undertakes no obligation to publicly update any
forward-looking statements, whether as a result of new information,
future presentations or otherwise, except as required by applicable
law.
Contact:
Implant Sciences Corporation
Company Contact:
Robert Liscouski
978-752-1700 x 116
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/implant-sciences-continues-to-innovate---granted-three-more-us-patents-for-trace-detection-300080945.html
SOURCE Implant Sciences Corporation